{"id":"W4311765023","doi":"10.1016/j.eururo.2022.11.025","title":"Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26]","year":2022,"lang":"en","type":"erratum","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Olaparib; Pembrolizumab; Prostate cancer; Oncology; Internal medicine; Cohort; Urology; Gynecology; Cancer; Immunotherapy; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002608526,0.001510821,0.001787397,0.0022278,0.001655295,0.002707056,0.001874133,0.00401843,0.1334105],"category_scores_gemma":[0.03841813,0.0009564989,0.00203851,0.001609415,0.000997254,0.001204271,0.001246691,0.006690829,0.07921556],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002636505,"about_ca_system_score_gemma":0.003329751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01527939,"about_ca_topic_score_gemma":0.02142375,"domain_scores_codex":[0.9968733,0.0005785198,0.0005698136,0.0004051588,0.001271418,0.0003017749],"domain_scores_gemma":[0.9789364,0.006605483,0.001059877,0.00101489,0.01123157,0.001151894],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001603825,0.000003786669,0.00002727312,0.00004147469,0.00000566228,0.00005093171,0.000003510804,0.00001116574,0.00001549394,0.0000709343,0.997735,0.002018595],"study_design_scores_gemma":[0.00008716626,0.00004138291,0.001049701,0.0002702561,0.00005448662,0.0005829509,0.00003216021,0.0001661416,0.0003129639,0.0008413745,0.9965301,0.00003126702],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0001348357,0.001214257,0.000592384,0.07622083,0.9111341,0.00004939993,0.003396122,0.0005230408,0.006735011],"genre_scores_gemma":[0.008189629,0.007418352,0.003580761,0.2353983,0.3920581,0.0003027631,0.01068514,0.002176696,0.3401903],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.1334105,"threshold_uncertainty_score":0.4463025,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03189533556481511,"score_gpt":0.3104238590029311,"score_spread":0.278528523438116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}